Lumos Pharma (LUMO) and Double Point Ventures announced the completion of the previously announced tender offer for Lumos Pharma’s shares at a purchase price of $4.25 per share in cash at ...

Lumos Pharma (LUMO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward White from H.C. Wainwright reiterated a Buy rating on the stock ...

--Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the appointment of An van Es-Johansson, M.D., to its Board of Directors ...

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company ...